Unaudited Interim Results to 30 June 2025
RNS Announcements
Directorate change
11 January 2024
ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to
support cardiometabolic health, announces that Mikkel Hvid-Hansen, Commercial
Director and Board member of the Company, has resigned from his position to pursue
other opportunities, effective from 28 February 2024.
Separately, the Company announces the appointment of Michael Litichevski as Head of
Global Sales as of 1 January 2024. The appointment of Michael is part of the
Company's strategy to build a strong commercial team to support the long-term growth
of ProBiotix. Michael joins ProBiotix from Lactobio, a microbial solutions and
microbiome skincare company with a live bacteria business. He has over 25 years'
experience in building B2B segments with more than 11 years of this specifically
within the probiotics dietary supplements industry. He was previously VP of Sales at
Deerland Probiotics & Enzymes, VP sales of Bifodan and has worked for large
organisations such as Orkla brands and Nycomed. Michael has extensive
experience with the commercialisation of innovative and high-quality probiotic
solutions which is in line with the Company's strategical direction of finished
supplement dosage format. He has good connections in the industry and has the
ability to create strong and valuable partnerships.
Steen Andersen, CEO of ProBiotix Health plc commented: “We are sad
to see Mikkel leave us but wish him well in his future endeavours. He has held
the role of European Sales Director and Commercial Director at ProBiotix for the
last four years, since before we listed on Aquis, and has brought a wealth of
knowledge and expertise to the role. The Board would like to thank him for his
service and guidance.
“We would also like to extend a warm welcome to Michael as our new Head of Global Sales. I am confident that he will be a huge asset to the commercial team and will greatly contribute to building our B2B business both locally and globally. He brings vast experience in sales leadership combined with scientific knowledge from global leading probiotic companies to support ProBiotix's strategy and sales on an international level.”
For further information, please contact:
ProBiotix Health plc | https://probiotixhealth-ir.com/ |
Steen Andersen, Chief Executive | Contact via Walbrook below |
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | Tel: 020 7469 0930 |
Mark Anwyl | |
Duncan Vasey | |
Walbrook PR Ltd | probiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).Aquis-listed ProBiotix Health
taps into demand for
cardiovascular disease treatments
Stephen O'Hara | 23
February 2023
IG UK | Youtube